References
- Aday, J. S., C. M. Mitzkovitz, E. K. Bloesch, C. C. Davoli, and A. K. Davis. 2020b. Long-term effects of psychedelic drugs: A systematic review. Neuroscience and Biobehavioral Reviews 113 (June):179–89. doi:https://doi.org/10.1016/j.neubiorev.2020.03.017.
- Aday, J. S., E. K. Bloesch, and C. C. Davoli. 2020a. 2019: A year of expansion in psychedelic research, industry, and deregulation. Drug Science, Policy and Law 6 (January):2050324520974484. doi:https://doi.org/10.1177/2050324520974484.
- Agin-Liebes, G. I., T. Malone, M. M. Yalch, S. E. Mennenga, K. Linnae Ponté, J. Guss, A. P. Bossis, J. Grigsby, S. Fischer, and S. Ross. 2020. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of Psychopharmacology 34 (2):155–66. doi:https://doi.org/10.1177/0269881119897615.
- Alpert, R. 1969. “LSD and Sexuality.” Psychedelic Review 10: 21–24.
- Andersen, K. A. A., R. Carhart–Harris, D. J. Nutt, and D. Erritzoe. 2021. Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. Acta Psychiatrica Scandinavica 143 (2):101–18. doi:https://doi.org/10.1111/acps.13249.
- Anderson, B. T., A. Danforth, R. Daroff Prof, C. Stauffer, E. Ekman, G. Agin-Liebes, A. Trope, M. T. Boden, P. J. Dilley, J. Mitchell, et al. 2020. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study. EClinicalMedicine 27 (October):100538. doi:https://doi.org/10.1016/j.eclinm.2020.100538.
- Argento, E., M. Braschel, M. Zach Walsh, E. Socias, and K. Shannon. 2018. The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women. Journal of Psychopharmacology 32 (12):1385–91. doi:https://doi.org/10.1177/0269881118798610.
- Barnett, B. S., W. O. Siu, and H. G. Pope. 2018. A survey of American psychiatrists’ attitudes toward classic hallucinogens. The Journal of Nervous and Mental Disease 206 (6):476–80. doi:https://doi.org/10.1097/NMD.0000000000000828.
- Beaussant, Y., J. Sanders, Z. Sager, J. A. Tulsky, I. M. Braun, C. D. Blinderman, A. P. Bossis, and I. Byock. 2020. Defining the roles and research priorities for psychedelic-assisted therapies in patients with serious illness: Expert Clinicians’ and investigators’ perspectives. Journal of Palliative Medicine 23 (April):1323–34. doi:https://doi.org/10.1089/jpm.2019.0603.
- Carhart-Harris, R. L., M. Kaelen, M. G. Whalley, M. Bolstridge, A. Feilding, and D. J. Nutt. 2015. “LSD enhances suggestibility in healthy volunteers. Psychopharmacology 232 (4):785–94. doi:https://doi.org/10.1007/s00213-014-3714-z.
- Ching, T. H. W. 2020. Intersectional insights from an MDMA-assisted psychotherapy training trial: An open letter to racial/ethnic and sexual/gender minorities. Journal of Psychedelic Studies 4 (1):61–68. doi:https://doi.org/10.1556/2054.2019.017.
- Davis, A. K., F. S. Barrett, D. G. May, M. P. Cosimano, N. D. Sepeda, M. W. Johnson, P. H. Finan, and R. R. Griffiths. 2020. Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry (November). doi:https://doi.org/10.1001/jamapsychiatry.2020.3285.
- Davis, A. K., S. So, R. Lancelotta, J. P. Barsuglia, and R. R. Griffiths. 2019. 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. The American Journal of Drug and Alcohol Abuse 45 (2):161–69. doi:https://doi.org/10.1080/00952990.2018.1545024.
- Doona, M. E., L. A. Haggerty, and S. K. Chase. 1997. Nursing presence: An existential exploration of the concept. Scholarly Inquiry for Nursing Practice 11 (1):3–16. discussion 17–20.
- Dorsen, C., J. Palamar, and M. G. Shedlin. 2019. Ceremonial ‘plant medicine’use and its relationship to recreational drug use: An exploratory study. Addiction Research & Theory 27 (2):68–75. doi:https://doi.org/10.1080/16066359.2018.1455187.
- Dylan-Robbins, S. 2015. The New Yorker: Magic mushrooms and the healing trip.
- Eckart, T., and S. Eckart. 2019. Oregon psilocybin services Act. https://cdn.ballotpedia.org/images/b/ba/Oregon_IP_34.pdf#page=1
- Ferrell, B. R., M. L. Twaddle, A. Melnick, and D. E. Meier. 2018. National consensus project clinical practice guidelines for quality palliative care guidelines, 4th ed. Journal of Palliative Medicine 21 (12):1684–89. doi:https://doi.org/10.1089/jpm.2018.0431.
- Garcia-Romeu, A., A. K. Davis, F. Erowid, E. Erowid, R. R. Griffiths, and M. W. Johnson. 2019. Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology (Oxford, England) 33 (May):269881119845793. doi:https://doi.org/10.1177/0269881119845793.
- George, J. R., T. I. Michaels, J. Sevelius, and M. T. Williams. 2019. The psychedelic renaissance and the limitations of a white-dominant medical framework: A call for indigenous and ethnic minority inclusion. Journal of Psychedelic Studies 4 (1): 1–12.
- Griffiths, R. R., M. W. Johnson, M. A. Carducci, A. Umbricht, W. A. Richards, B. D. Richards, M. P. Cosimano, and M. A. Klinedinst. 2016. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology (Oxford, England) 30 (12):1181–97. doi:https://doi.org/10.1177/0269881116675513.
- Guerra-Doce, E. 2015. Psychoactive substances in prehistoric times: Examining the archaeological evidence. Time and Mind 8 (1):91–112. doi:https://doi.org/10.1080/1751696X.2014.993244.
- Hendricks, P. S., C. B. Thorne, C. Brendan Clark, D. W. Coombs, and M. W. Johnson. 2015. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. Journal of Psychopharmacology 29 (3):280–88. doi:https://doi.org/10.1177/0269881114565653.
- Johansen, P.-Ø., and T. S. Krebs. 2015. Psychedelics not linked to mental health problems or suicidal behavior: A population study. Journal of Psychopharmacology (Oxford, England) 29 (3):270–79. doi:https://doi.org/10.1177/0269881114568039.
- Johnson, M. W., P. S. Hendricks, F. S. Barrett, and R. R. Griffiths. 2019. Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics 197 (May):83–102. doi:https://doi.org/10.1016/j.pharmthera.2018.11.010.
- Johnson, M. W., W. A. Richards, and R. R. Griffiths. 2008. Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology (Oxford, England) 22 (6):603–20. doi:https://doi.org/10.1177/0269881108093587.
- Kissane, D. W. 2000. Psychospiritual and existential distress. The challenge for palliative care. Australian Family Physician 29 (11):1022–25.
- Knopf, A. 2020. Drug decriminalization measure in Oregon would not increase treatment funding. Alcoholism & Drug Abuse Weekly 32 (46):1–3. doi:https://doi.org/10.1002/adaw.32905.
- MAPS. 2019. Statement: Public announcement of ethical violation by former MAPS-sponsored Investigators.” MAPS. 2019. https://maps.org/news/posts/7749-statement-public-announcement-of-ethical-violation-by-former-maps-sponsored-investigators
- Marks, M. 2020. Controlled Substance Regulation for the COVID-19 Mental Health Crisis. 72 Administrative Law Review 649.
- Marlan, D. 2019. Beyond cannabis: Psychedelic decriminalization and social justice. Lewis & Clark L. Rev 23:851.
- Martin, A. J. 1962. The treatment of twelve male homosexuals with ‘L.S.D.’ (Followed by a detailed account of one of them who was a psychopathic personality). Acta Psychotherapeutica et Psychosomatica 10 (5):394–402. doi:https://doi.org/10.1159/000285648.
- McLeroy, K. R., D. Bibeau, A. Steckler, and K. Glanz. 1988. An ecological perspective on health promotion programs. Health Education Quarterly 15 (4):351–77. doi:https://doi.org/10.1177/109019818801500401.
- Michaels, T. I., J. Purdon, A. Collins, and M. T. Williams. 2018. Inclusion of people of color in psychedelic-assisted psychotherapy: A review of the literature. BMC Psychiatry 18 (1):245. doi:https://doi.org/10.1186/s12888-018-1824-6.
- Morse, J. M. 1990. Qualitative nursing research: A contemporary dialogue. Newbury Park: SAGE Publications.
- Neitzke-Spruill, L. 2020. Race as a component of set and setting: How experiences of race can influence psychedelic experiences. Journal of Psychedelic Studies 4 (1):51–60. doi:https://doi.org/10.1556/2054.2019.022.
- Noorani, T., A. Garcia-Romeu, T. C. Swift, R. R. Griffiths, and M. W. Johnson. 2018. Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. Journal of Psychopharmacology 32 (June):756–69. doi:https://doi.org/10.1177/0269881118780612.
- Pessin, H., N. Fenn, E. Hendriksen, A. P. DeRosa, and A. Applebaum. 2015. Existential distress among caregivers or professionals taking care of dying patients. Current Opinion in Supportive and Palliative Care 9 (1):77–86. doi:https://doi.org/10.1097/SPC.0000000000000116.
- Phelps, J. 2017. Developing guidelines and competencies for the training of psychedelic therapists. Journal of Humanistic Psychology 57 (5):450–87. doi:https://doi.org/10.1177/0022167817711304.
- Pollan,Michael. 2018. How to change your mind : What the new science of psychedelics teaches us about consciousness, dying, addiction, depression, and transcendence.” New York: Penguin Press.
- Puchalski, C. M., S. D. W. King, and B. R. Ferrell. 2018. Spiritual considerations. Hematology/Oncology Clinics of North America, Pain Control 32 (3):505–17. doi:https://doi.org/10.1016/j.hoc.2018.01.011.
- Reiche, S., L. Hermle, S. Gutwinski, H. Jungaberle, P. Gasser, and T. Majić. 2018. Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review. Progress in Neuro-Psychopharmacology & Biological Psychiatry 81 (February):1–10. doi:https://doi.org/10.1016/j.pnpbp.2017.09.012.
- Ross, S. 2018. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. International Review of Psychiatry 30 (4):317–30. doi:https://doi.org/10.1080/09540261.2018.1482261.
- Roze des Ordons, A. L., T. Sinuff, H. T. Stelfox, J. Kondejewski, and S. Sinclair. 2018. Spiritual distress within inpatient settings—A scoping review of patients’ and families’ experiences. Journal of Pain and Symptom Management 56 (1):122–45. doi:https://doi.org/10.1016/j.jpainsymman.2018.03.009.
- Sandelowski, M. 2000. Whatever happened to qualitative description?. Research in Nursing & Health 23 (4):334–40. doi:https://doi.org/10.1002/1098-240X(200008)23:4<334::aid-nur9>3.0.CO;2-G.
- Strickland, J. C., A. Garcia-Romeu, and M. W. Johnson. 2020. Set and setting: A randomized study of different musical genres in supporting psychedelic therapy. ACS Pharmacology & Translational Science (December). doi:https://doi.org/10.1021/acsptsci.0c00187.
- Swift, T. C., A. B. Belser, G. Agin-Liebes, N. Devenot, H. L. Sara Terrana, J. G. Friedman, A. P. Bossis, and S. Ross. 2017. Cancer at the dinner table: Experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress. Journal of Humanistic Psychology 57 (5):488–519. doi:https://doi.org/10.1177/0022167817715966.
- Uthaug, M. V., R. Lancelotta, K. van Oorsouw, K. P. C. Kuypers, N. Mason, J. Rak, A. Šuláková, R. Jurok, M. Maryška, M. Kuchař, et al. 2019. A Single inhalation of vapor from dried toad secretion containing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology 236 (9):2653–66. doi:https://doi.org/10.1007/s00213-019-05236-w.
- Williams, M. T., A. K. Davis, Y. Xin, N. D. Sepeda, P. C. Grigas, S. Sinnott, and A. M. Haeny. 2020. People of color in North America report improvements in racial trauma and mental health symptoms following psychedelic experiences. Drugs: Education, Prevention and Policy 1–12. doi:https://doi.org/10.1080/09687637.2020.1854688.
- Williams, M. T., S. Reed, and J. George. 2020. Culture and psychedelic psychotherapy: Ethnic and racial themes from three black women therapists. Journal of Psychedelic Studies 4 (3):125–38. doi:https://doi.org/10.1556/2054.2020.00137.
- Williams, M. T., S. Reed, and R. Aggarwal. 2020. Culturally informed research design issues in a study for MDMA-assisted psychotherapy for posttraumatic stress disorder. Journal of Psychedelic Studies 4 (1):40–50. doi:https://doi.org/10.1556/2054.2019.016.